alpha-aminopyridine has been researched along with Leishmaniasis, American in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S; Kima, PE; Nandan, D; Reiner, NE; Schwartz, B; Yu, Y; Zhang, N | 1 |
1 other study(ies) available for alpha-aminopyridine and Leishmaniasis, American
| Article | Year |
|---|---|
Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania.
Topics: Administration, Oral; Aminopyridines; Animals; Humans; Imidazoles; Leishmania donovani; Leishmaniasis, Cutaneous; Leishmaniasis, Visceral; Macrophages; Mice; Parasite Load; Proto-Oncogene Proteins c-akt; Spleen | 2018 |